We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0NZQ market cap is 0. The company's latest EPS is RON and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Total Revenue | 722.82M | 721.21M | 779.63M | 916.25M | 1.12B |
| Operating Income | 9.13M | 15.62M | 18.58M | 10.38M | 18.06M |
| Net Income | 7.52M | 6.75M | 10.73M | 9.22M | 7.72M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Total Assets | 674.44M | 651.17M | 667.34M | 770.25M | 807.78M |
| Total Liabilities | 485.85M | 449.29M | 447.75M | 536.76M | 555.92M |
| Total Equity | 188.59M | 201.87M | 219.59M | 233.49M | 251.85M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| RON (RON) | RON (RON) | RON (RON) | RON (RON) | RON (RON) | |
| Operating | 8.45M | -8.64M | 14.65M | 31.93M | 40.49M |
| Investing | -42.89M | -17.67M | -28.17M | -14.76M | -14.52M |
| Financing | -1.12M | -10.45M | -24.47M | -12.41M | -24.88M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 511.27M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Ropharma Sa |
| Address |
str. iuliu maniu nr 55 brasov 500091 |
| Website | https://www.ropharma.ro |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
